Skip to main
GOVX
GOVX logo

Geovax Labs (GOVX) Stock Forecast & Price Target

Geovax Labs (GOVX) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 78%
Buy 22%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Geovax Labs Inc. is positioned favorably within the expanding biodefense and vaccine markets, as evidenced by the substantial government funding aimed at accelerating the development of new vaccines and treatments. The company’s ongoing commitment to vaccine accessibility, particularly in Clade 1-endemic regions, aligns with global health priorities and enhances the potential impact of its offerings. Additionally, Geovax's innovative GEO-MVA vaccine contributes to a diversified vaccine supply chain, thereby strengthening U.S. domestic manufacturing capabilities and resilience against future outbreaks.

Bears say

Geovax Labs faces a negative outlook primarily due to the high cost of its preferred vaccine, which, at up to $270 per dose, poses significant barriers to widespread vaccination and contributes to global access inequalities. Additionally, delays in vaccine distribution and limited production capacity have resulted in unused stockpiles, particularly in Africa, where health agencies requested 20 million doses for 2025 but only 2 to 5 million doses are projected to be available. Furthermore, the reliance on a single supplier for vaccine production raises the risk of supply chain disruptions, further complicating efforts to address health inequalities and mitigate the ongoing threat of infectious diseases.

Geovax Labs (GOVX) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 78% of analysts recommend a Strong Buy, 22% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Geovax Labs (GOVX) Forecast

Analysts have given Geovax Labs (GOVX) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Geovax Labs (GOVX) has a Strong Buy consensus rating as of Jul 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Geovax Labs (GOVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.